
PMC:7594251 / 62794-64111
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T35535 | 376-384 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T456 | 33-36 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T457 | 467-475 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | labeling |
T458 | 588-595 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | labeled |
T459 | 649-650 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T460 | 744-751 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signals |
T461 | 820-827 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signals |
T462 | 933-934 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T463 | 1212-1218 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signal |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T134 | 51-57 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
T58958 | 85-89 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T49808 | 206-212 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
T13572 | 220-228 | Chemical | denotes | solution | http://purl.obolibrary.org/obo/CHEBI_75958 |
T138 | 359-368 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
T93907 | 376-384 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T95011 | 429-433 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T91115 | 735-743 | Chemical | denotes | molecule | http://purl.obolibrary.org/obo/CHEBI_25367 |
T6507 | 1098-1107 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T432 | 0-100 | Sentence | denotes | Diffusion-based NMR spectroscopy has advantages in ligand based screening applied to drug discovery. |
T433 | 101-235 | Sentence | denotes | For example, Diffusion Ordered Spectroscopy (DOSY) does not require prior separation/purification of the ligand/target solution [298]. |
T434 | 236-648 | Sentence | denotes | Diffusion based NMR allows simultaneous determination of diffusion coefficients in multicomponent systems containing large molecules (i.e., proteins) and possible binding partners (i.e., small drug compounds) [285], and no special labeling or contrasting agents are required, though their use is not exclusively inhibited (for an example of the use of labeled compounds in diffusion NMR spectroscopy, see [299]). |
T435 | 649-767 | Sentence | denotes | A problem occurs when there is significant chemical shift overlap between the binding molecule signals and the target. |
T436 | 768-942 | Sentence | denotes | This situation makes it hard to distinguish the NMR signals [300], and the calculations typically assign an intermediate value to the diffusion rate (i.e., one gets a smear). |
T437 | 943-1075 | Sentence | denotes | Multidimensional diffusion NMR pulse sequences are available [301], which may help resolve spectral overlap in 1D experiments [300]. |
T438 | 1076-1174 | Sentence | denotes | Another issue is that molecules in chemical databases may have generally low solubility [302,303]. |
T439 | 1175-1317 | Sentence | denotes | Low solubility decreases the overall signal intensity and therefore makes accurately measuring diffusion experiments far more difficult [304]. |